{"BackgroundA": [0], "single,": [1], "high": [2], "priming": [3], "dose": [4], "of": [5, 39, 51, 71, 237], "tremelimumab": [6, 74], "(anti-cytotoxic": [7], "T": [8], "lymphocyte\u2013associated": [9], "antigen": [10], "4)": [11], "plus": [12, 79], "durvalumab": [13, 80, 87, 114, 130, 201], "(anti\u2013programmed": [14], "cell": [15], "death": [16], "ligand-1),": [17], "an": [18], "infusion": [19], "regimen": [20], "termed": [21], "STRIDE": [22, 106, 128, 187], "(Single": [23], "Tremelimumab": [24], "Regular": [25], "Interval": [26], "Durvalumab),": [27], "showed": [28], "encouraging": [29], "clinical": [30], "activity": [31], "and": [32, 60, 160, 178, 244], "safety": [33], "in": [34], "a": [35, 118], "phase": [36, 46], "2": [37], "trial": [38], "unresectable": [40, 57, 263], "hepatocellular": [41, 58, 264], "carcinoma.MethodsIn": [42], "this": [43], "global,": [44], "open-label,": [45], "3": [47], "trial,": [48], "the": [49, 52], "majority": [50], "patients": [53, 123, 238, 261], "we": [54], "enrolled": [55], "with": [56, 149, 158, 168, 200, 239, 242, 246, 262], "carcinoma": [59], "no": [61], "previous": [62], "systemic": [63], "treatment": [64], "were": [65, 124], "randomly": [66, 125], "assigned": [67, 126], "to": [68, 127, 147, 156, 166, 195, 205, 213, 258], "receive": [69], "one": [70, 77], "three": [72, 227], "regimens:": [73], "(300": [75], "mg,": [76], "dose)": [78], "(1500": [81, 88], "mg": [82, 89, 96], "every": [83, 90], "4": [84, 91], "weeks;": [85], "STRIDE),": [86], "weeks),": [92], "or": [93, 132], "sorafenib": [94, 116, 133, 189, 206, 259], "(400": [95], "twice": [97], "daily).": [98], "The": [99, 135, 181], "primary": [100], "objective": [101], "was": [102, 117, 139, 175, 190, 203, 221, 256], "overall": [103, 111, 137, 182, 250], "survival": [104, 112, 138, 171, 183, 199, 220, 251], "for": [105, 110, 113, 186, 235, 260], "versus": [107, 115, 188, 252], "sorafenib.": [108, 169, 253], "Noninferiority": [109], "secondary": [119], "objective.ResultsIn": [120], "total,": [121], "1171": [122], "(n=393),": [129], "(n=389),": [131], "(n=389).": [134], "median": [136], "16.43": [140], "months": [141, 152, 162, 174], "(95%": [142, 153, 163], "confidence": [143], "interval": [144], "[CI],": [145], "14.16": [146], "19.58)": [148], "STRIDE,": [150, 240], "16.56": [151], "CI,": [154, 164, 193, 211], "14.06": [155], "19.12)": [157], "durvalumab,": [159, 243], "13.77": [161], "12.25": [165], "16.13)": [167], "Overall": [170, 198], "at": [172], "36": [173], "30.7%,": [176], "24.7%,": [177], "20.2%,": [179], "respectively.": [180], "hazard": [184], "ratio": [185], "0.78": [191], "(96.02%": [192], "0.65": [194], "0.93;": [196], "P=0.0035).": [197], "monotherapy": [202, 255], "noninferior": [204, 257], "(hazard": [207], "ratio,": [208], "0.86;": [209], "95.67%": [210], "0.73": [212], "1.03;": [214], "noninferiority": [215], "margin,": [216], "1.08).": [217], "Median": [218], "progression-free": [219], "not": [222], "significantly": [223, 248], "different": [224], "among": [225], "all": [226], "groups.": [228], "Grade": [229], "3/4": [230], "treatment-emergent": [231], "adverse": [232], "events": [233], "occurred": [234], "50.5%": [236], "37.1%": [241], "52.4%": [245], "sorafenib.ConclusionsSTRIDE": [247], "improved": [249], "Durvalumab": [254], "carcinoma.": [265], "(Funded": [266], "by": [267], "AstraZeneca;": [268], "ClinicalTrials.gov": [269], "number,": [270], "NCT03298451.)": [271]}